Understand the study
Thymosin Beta-4 and Dry Eye: Why the Main Result Matters
Understand eye-surface staining, discomfort scores and the difference between main and secondary outcomes.
How can researchers measure dry eye?
Researchers can ask about discomfort and examine the eye surface. Corneal staining uses a dye to help identify areas of surface disruption. A symptom score and a staining score address different aspects: how a person feels and what a test shows. Neither should be renamed as the other.
What preparation was studied?
The trial tested a thymosin beta-4 ophthalmic solution, RGN-259, against placebo in 72 participants. Treatment lasted 28 days. The clinical eye-drop preparation is part of the experiment’s identity; it cannot be replaced in the description by a generic peptide powder. [1]
- 01Main planned outcomes
- 02Secondary observations
- 03Do not replace one with the other
What were the main outcomes?
The planned primary measures were ocular discomfort and inferior corneal staining at the specified visit on day 29. Neither showed a significant between-group difference. A fair account should say this before discussing favorable secondary findings. [1]
What did the secondary measures show?
The paper reported a 27% lower discomfort score in the controlled adverse-environment test on day 28 and improvements in central and superior corneal staining. That 27% describes a particular score in a particular test. It is not a cure rate or a percentage of people whose dry eye disappeared. [1]
Why do the day and location matter?
Results can depend on when and where a measurement is made. Changing the visit or the part of the cornea changes the question. Imagine checking a room’s temperature near a window and at its center: the readings may differ without either being invented. The report needs to retain the measurement’s exact meaning.
What must match before linking a product?
Check the full peptide sequence, form and formulation. The related TB-500/Thymosin β4 Acetate catalog link is provided for material identification, not as an equivalent eye drop. Literature about a clinical ophthalmic solution supplies neither sterility evidence nor eye-use instructions for a catalog research material.
Explore the research topic
Related research products
TB-500 (Thymosin β4 Acetate)
Tissue-repair research
View product
BPC-157
Tissue-repair research
View product
GHK-Cu
Tissue-repair research
View productImages illustrate the catalog. Related products are further reading, not claims of equal effects or interchangeability.
Original research and reading notes
Study amounts and preparations identify experimental conditions, not recommended use. AI-assisted research explanation; sources checked 11 October 2026. NHD catalog materials are for research, development and manufacturing, not human or veterinary use.